Suven Life Sciences Limited
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
What Suven files
- Others58
- Updates17
- Board Meeting14
- Important5
- QIP/Rights/Pref.3
- Insider Trade3
Suven Life Sciences completed patient enrollment for its global Phase-3 Masupirdine study (SUVN-502) for Alzheimer’s Dementia agitation. 424 patients were randomized. Topline results are anticipated by May 2027, signaling progress in its CNS pipeline.
Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
Monitoring Agency Report for the quarter ended June 30, 2026
Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
Suven Life Sciences' Board approved Q1 financial results. Consolidated net loss was ₹127.61 Cr, with total income at ₹11.09 Cr. Clinical trials advanced with 95% enrollment for SUVN-502 Phase 3 and SUVN-G3031 Phase 3 initiated. Proceeds from preferential warrants continue to be received.